Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr-/- mice

Due to their ability to promote positive effects across all of the lipoprotein classes, cholesteryl ester transfer protein (CETP) inhibitors are currently being developed as therapeutic agents for cardiovascular disease. In these studies, we compared an antisense oligonucleotide (ASO) inhibitor of C...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Thomas A. Bell, III, Mark J. Graham, Richard G. Lee, Adam E. Mullick, Wuxia Fu, Dan Norris, Rosanne M. Crooke
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Elsevier 2013-10-01
Rangatū:	Journal of Lipid Research
Ngā marau:	cholesteryl ester transfer protein cardiovascular disease low density lipoprotein lipoprotein metabolism
Urunga tuihono:	http://www.sciencedirect.com/science/article/pii/S0022227520352913
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!